Equities
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)1,592.00
  • Today's Change2.50 / 0.16%
  • Shares traded107.67k
  • 1 Year change-26.91%
  • Beta1.1277
Data delayed at least 15 minutes, as of Nov 08 2024 15:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of DKK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments28,13522,32419,338
Total Receivables, Net4,9475,8943,398
Total Inventory570--
Prepaid expenses------
Other current assets, total------
Total current assets33,13928,21822,736
Property, plant & equipment, net1,6411,322975
Goodwill, net------
Intangibles, net101146254
Long term investments134133371
Note receivable - long term624827
Other long term assets------
Total assets35,28930,11924,627
LIABILITIES
Accounts payable330245350
Accrued expenses637481296
Notes payable/short-term debt000
Current portion long-term debt/capital leases907462
Other current liabilities, total1,4271,023860
Total current liabilities2,4841,8231,568
Total long term debt680523363
Total debt770597425
Deferred income tax------
Minority interest------
Other liabilities, total515491500
Total liabilities3,6792,8372,431
SHAREHOLDERS EQUITY
Common stock666666
Additional paid-in capital12,46112,30912,029
Retained earnings (accumulated deficit)19,02314,80910,020
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total609881
Total equity31,61027,28222,196
Total liabilities & shareholders' equity35,28930,11924,627
Total common shares outstanding656565
Treasury shares - common primary issue0.740.590.29
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.